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within and 74 (46,0%) outside of clinical trials (33 =
20,5% undeﬁned). For HD patients, mean hospital costs
and mean costs of chemotherapy during the ﬁrst 6 months
after initial diagnosis were €6.336,95 and €10.039,73
respectively, for NHL patients €9.787,15 and €6.720,93,
for CLL €1.055,31 and €749,04 respectively, and for
MM patients €9.016,12 and €4.870,57.
CONCLUSIONS: The continuation of this project will
make it possible to determine cost-of-illness and cost-
effectiveness ratios of different treatment modalities for
patients with malignant lymphomas and to develop
guidelines for clinical pathways.
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OBJECTIVE: To quantify the economic effect on 
employers when the spouse or dependent of an employee
is diagnosed with cancer.
METHODS: Costs based on claims data for ﬁve major
employers (number of employees exceeds 100,000) over
the period of 1995–1998 were analyzed from the employ-
ers’ perspectives. The employers’ burden is measured in
terms of direct health-related costs and indirect produc-
tivity costs (i.e., both lost worktime and reduced at-work
performance). Costs for employees who had a family
member with cancer were compared to costs for employ-
ees who did not. For employees who had a family member
with cancer, the relationship between the employee’s costs
and the timing of the family member’s cancer diagnosis
and treatment was examined. Regression analyses were
used to estimate the incremental costs associated with
caring for a family member before, during and after the
diagnosis of cancer.
RESULTS: Caregiving costs were most pronounced
during the 3-month period leading up to and the 3-month
period following diagnosis. Loss of productivity ac-
counted for most of the incremental costs and reached
approximately $1,500 per employee per year. Medical
and drug costs added approximately $230 per employee
per year. When a family member suffered from anemia in
addition to cancer, the costs during the anemia period
(deﬁned as four weeks preceding through four weeks 
following a claims diagnosis of anemia) were over 40
percent higher than in comparable cancer periods without
anemia.
CONCLUSIONS: The economic impact of caregiving for
a family member with cancer is signiﬁcant, and translates
into increased workplace costs. Moreover, this cost in-
crease is more pronounced when cancer-related anemia is
present. These patterns suggest that programs to prevent
or quickly treat a family member’s cancer and any related
anemia could yield indirect beneﬁts to employers by
reducing the burden on employees as caregivers.
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Colorectal cancer is the third most common form of
cancer, representing an estimated 135,400 cases and
56,700 deaths in 2001. Because early detection of col-
orectal cancer can signiﬁcantly reduce 1-year and 5-year
relative survival rates, screening strategies are highly 
recommended. More research into the cost-effectiveness
of new screening technique compared to current methods
is needed.
OBJECTIVES: This analysis attempts to compare the
cost-effectiveness of conventional colonoscopy and
virtual colonoscopy (CT scan) as screening strategies for
the prevention of colorectal cancers in the general 
population.
METHODS: A literature review was conducted to obtain
all relevant costs and probabilities. A spreadsheet model
was constructed to perform the analysis using a hypo-
thetical cohort of the general population over age 50
years from the societal perspective using 2001 US dollars.
A series of one-way sensitivity analysis were performed
on all costs and probabilities obtained from published 
literature.
RESULTS: In the base-case analysis, the number of 
life-years saved per 100,000 was 4000 and 5600 for
virtual and conventional colonoscopy respectively. The
average cost per life-year saved was estimated at $48,200
for virtual colonoscopy and $52,200 for conventional
colonoscopy compared to no screening. The incremental
cost-effectiveness ratio (ICER) of conventional col-
onoscopy versus virtual colonoscopy was $62,100. The
model was most sensitive to the ranges used for the 
discount rate, sensitivity of conventional colonoscopy,
and the cost of conventional colonoscopy.
CONCLUSION: The ICER of conventional to virtual
colonoscopy is borderline unfavorable. Nevertheless,
because of the greater number of life-years saved with
conventional colonoscopy, it appears more favorable than
virtual colonoscopy. Due to the closeness in CEA results,
and the substantial changes with different parameter
assumptions, e.g. combinations of screening strategies
and differences in compliance rates, further data and
analyses are needed to derive a robust conclusion.
PCN8
COST-EFFECTIVENESS ANALYSIS OF LHRH
AGONISTS IN THE TREATMENT OF
METASTATIC PROSTATE CANCER
Iskedjian M1, Hemels M2, Iscoe N3, Fleshner N4, Einarson T2
1Pharmideas Research and Consulting Inc, Oakville, ON,
Canada; 2University of Toronto,Toronto, ON, Canada;
3Toronto-Sunnybrook Regional Cancer Centre,Toronto, ON,
Canada; 4Sunnybrook and Women’s Health Sciences Center,
Toronto, ON, Canada
